A single infusion of zimislecel, an investigational stem cell-based therapy, restored physiologic islet function and ...

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

CHICAGO -- An investigational allogeneic stem cell-derived islet-cell therapy helped almost all patients with type 1 diabetes ...

A study may have found a cure for type 1 diabetes. Here, experts explain how the treatment, zimislecel, works and what it ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

In phase 2 of the FORWARD study, 83% of participants with type 1 diabetes achieved insulin independence a year after ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C. Wainwright reaffirmed its Buy rating on ...

Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit ...

An off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results, according to a new study.